Alto Neuroscience (ANRO) Receivables - Other (2023 - 2024)
Alto Neuroscience (ANRO) posted Receivables - Other of -$8000.0 for Q1 2024, down 200.0% sequentially from $8000.0 in Q4 2023, and down 121.62% YoY from $37000.0 in Q2 2023.
Powered by 
Analysis
Alto Neuroscience (ANRO) Receivables - Other (2023 - 2024) Analysis & Trends
Alto Neuroscience has reported Receivables - Other for 2 years, with the latest figure at -$8000.0 in Q1 2024.
- Quarterly Receivables - Other fell 121.62% year-over-year to -$8000.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was -$333000.0 (changed N/A YoY) and the FY2023 annual result came in at $8000.0, changed N/A from the prior year.
- Receivables - Other eased to -$8000.0 in Q1 2024 per ANRO's latest filing, from $8000.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $37000.0 in Q1 2023 and troughed at -$295000.0 in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Alto Neuroscience | 1.52 Bn | 1.52 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | -8,000.00 |
| Dec 31, 2023 | 8,000.00 |
| Sep 30, 2023 | -295,000.00 |
| Jun 30, 2023 | -67,000.00 |
| Mar 31, 2023 | 37,000.00 |